Replies to post #232585 on Amarin Corp Plc (AMRN)

[VuBru]

Raf - I suspect they will not release any results that they want to publish eventually, unless it is as a poster/talk at a major conference. Avoids giving information to potential rivals and insures there are no hiccups in publishing (if it is released formally by the company, a journal in theory could argue that it is not new information, although this is unlikely).

[lowlevelowl88]

Excellent question. I don't know. I want to believe there's something there, I just have no evidence other than the same abstracts we all have access to w/r/t EPA and liver function. But even if R-IT data didn't show a clear path for V (alone) in the NASH space, it makes terrific sense for V to be paired with a drug that is known to elevate trigs, and for one Co (to try) to own them both. The addition of V to the GILD trial may very well be part of their DD, but given they just started who knows how quickly they can get a look at that data...